A W Partin

Summary

Affiliation: Johns Hopkins University
Country: USA

Publications

  1. ncbi request reprint New serum tests for the diagnosis of prostate cancer
    Alexander Haese
    The James Buchanan Brady Urological Institute, The Johns Hopkins University School of Medicine, Baltimore, MD, U S A The Department of Urology, University Clinic Eppendorf, Hamburg, Germany
    Drugs Today (Barc) 37:607-616. 2001
  2. pmc Clinical validation of an epigenetic assay to predict negative histopathological results in repeat prostate biopsies
    Alan W Partin
    James Buchanan Brady Urological Institute, The Johns Hopkins University School of Medicine, Baltimore, Maryland Electronic address
    J Urol 192:1081-7. 2014
  3. ncbi request reprint Complexed prostate specific antigen improves specificity for prostate cancer detection: results of a prospective multicenter clinical trial
    Alan W Partin
    James Buchanan Brady Urological Institute, The Johns Hopkins Medical Institution, Baltimore, MD 21287, USA
    J Urol 170:1787-91. 2003
  4. ncbi request reprint Prostate-specific antigen and new serum biomarkers for evaluation of chemopreventive agents
    A W Partin
    James Buchanan Brady Urological Institute, The Johns Hopkins School of Medicine, Department of Urology, Baltimore, Maryland, USA
    Urology 57:132-6. 2001
  5. ncbi request reprint Surgical margin status after radical retropubic prostatectomy
    Masood A Khan
    James Buchanan Brady Urological Institute, The Johns Hopkins University School of Medicine, Jefferson Building Rm 157, 600 North Wolfe Street, Baltimore, MD 21287, USA
    BJU Int 95:281-4. 2005
  6. ncbi request reprint Cancer cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer as vaccines for the treatment of genitourinary malignancies
    W G Nelson
    Johns Hopkins Oncology Center, Baltimore, MD 21231, USA
    Cancer Chemother Pharmacol 46:S67-72. 2000
  7. ncbi request reprint Probability of biochemical recurrence by analysis of pathologic stage, Gleason score, and margin status for localized prostate cancer
    Masood A Khan
    Department of Urology, James Buchanan Brady Urological Institute and Johns Hopkins University School of Medicine, Johns Hopkins Hospital, Baltimore, Maryland 21287 2101, USA
    Urology 62:866-71. 2003
  8. pmc DNA Ploidy as surrogate for biopsy gleason score for preoperative organ versus nonorgan-confined prostate cancer prediction
    Sumit Isharwal
    James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland 21287 2101, USA
    Urology 73:1092-7. 2009
  9. ncbi request reprint Prostate-specific antigen doubling time in the identification of patients at risk for progression after treatment and biochemical recurrence for prostate cancer
    Glenn M Cannon
    Department of Urology, University of Pittsburgh, Pittsburgh, Pennsylvania 15232, USA
    Urology 62:2-8. 2003
  10. ncbi request reprint Does capsular incision at radical retropubic prostatectomy affect disease-free survival in otherwise organ-confined prostate cancer?
    D A Barocas
    James Buchanan Brady Urological Institute, Departments of Department ofUrology, Johns Hopkins Medical Institutions, Baltimore, Maryland, USA
    Urology 58:746-51. 2001

Detail Information

Publications103 found, 100 shown here

  1. ncbi request reprint New serum tests for the diagnosis of prostate cancer
    Alexander Haese
    The James Buchanan Brady Urological Institute, The Johns Hopkins University School of Medicine, Baltimore, MD, U S A The Department of Urology, University Clinic Eppendorf, Hamburg, Germany
    Drugs Today (Barc) 37:607-616. 2001
    ..c) 2001 Prous Science. All rights reserved...
  2. pmc Clinical validation of an epigenetic assay to predict negative histopathological results in repeat prostate biopsies
    Alan W Partin
    James Buchanan Brady Urological Institute, The Johns Hopkins University School of Medicine, Baltimore, Maryland Electronic address
    J Urol 192:1081-7. 2014
    ..Confirming an increased negative predictive value could help avoid unnecessary repeat biopsies...
  3. ncbi request reprint Complexed prostate specific antigen improves specificity for prostate cancer detection: results of a prospective multicenter clinical trial
    Alan W Partin
    James Buchanan Brady Urological Institute, The Johns Hopkins Medical Institution, Baltimore, MD 21287, USA
    J Urol 170:1787-91. 2003
    ....
  4. ncbi request reprint Prostate-specific antigen and new serum biomarkers for evaluation of chemopreventive agents
    A W Partin
    James Buchanan Brady Urological Institute, The Johns Hopkins School of Medicine, Department of Urology, Baltimore, Maryland, USA
    Urology 57:132-6. 2001
    ..This update will focus on a critical evaluation of prostate-specific antigen (PSA), percentage of free PSA, and human glandular kallikrein-2 (hK2) and how they may be used or misused for chemoprevention studies...
  5. ncbi request reprint Surgical margin status after radical retropubic prostatectomy
    Masood A Khan
    James Buchanan Brady Urological Institute, The Johns Hopkins University School of Medicine, Jefferson Building Rm 157, 600 North Wolfe Street, Baltimore, MD 21287, USA
    BJU Int 95:281-4. 2005
    ..Finally, there is a mini-review of conventional and alternative methods for providing analgesia in renal colic...
  6. ncbi request reprint Cancer cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer as vaccines for the treatment of genitourinary malignancies
    W G Nelson
    Johns Hopkins Oncology Center, Baltimore, MD 21231, USA
    Cancer Chemother Pharmacol 46:S67-72. 2000
    ....
  7. ncbi request reprint Probability of biochemical recurrence by analysis of pathologic stage, Gleason score, and margin status for localized prostate cancer
    Masood A Khan
    Department of Urology, James Buchanan Brady Urological Institute and Johns Hopkins University School of Medicine, Johns Hopkins Hospital, Baltimore, Maryland 21287 2101, USA
    Urology 62:866-71. 2003
    ....
  8. pmc DNA Ploidy as surrogate for biopsy gleason score for preoperative organ versus nonorgan-confined prostate cancer prediction
    Sumit Isharwal
    James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland 21287 2101, USA
    Urology 73:1092-7. 2009
    ..To evaluate nuclear morphometric alterations and clinicopathologic features for organ- vs nonorgan-confined prostate carcinoma (PCa) prediction...
  9. ncbi request reprint Prostate-specific antigen doubling time in the identification of patients at risk for progression after treatment and biochemical recurrence for prostate cancer
    Glenn M Cannon
    Department of Urology, University of Pittsburgh, Pittsburgh, Pennsylvania 15232, USA
    Urology 62:2-8. 2003
    ..Early observations of PSADT in men with recurrence are reviewed and the current literature is summarized to allow physicians to make an accurate assessment of a patient's risk of progression after isolated biochemical recurrence...
  10. ncbi request reprint Does capsular incision at radical retropubic prostatectomy affect disease-free survival in otherwise organ-confined prostate cancer?
    D A Barocas
    James Buchanan Brady Urological Institute, Departments of Department ofUrology, Johns Hopkins Medical Institutions, Baltimore, Maryland, USA
    Urology 58:746-51. 2001
    ....
  11. ncbi request reprint Serum acid phosphatase level and biochemical recurrence following radical prostatectomy for men with clinically localized prostate cancer
    M Han
    Department of Urology, James Buchanan Brady Urological Institute, The Johns Hopkins Medical Institutions, Baltimore, Maryland, USA
    Urology 57:707-11. 2001
    ..Proportional hazards modeling using preoperative variables demonstrated that the serum ACP level is an independent predictor of tumor recurrence following RRP...
  12. ncbi request reprint Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience
    M Han
    James Buchanan Brady Urological Institute, Department of Urology, Johns Hopkins Medical Institutions, Baltimore, Maryland, USA
    Urol Clin North Am 28:555-65. 2001
    ..Excellent long-term results can be obtained with RRP for early stage disease. The proportion of men with early stage prostate cancer will continue to increase with wide use of serum PSA testing and digital rectal examination...
  13. ncbi request reprint Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium
    A W Partin
    James Buchanan Brady Urological Institute and Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, Maryland, USA
    Urology 58:843-8. 2001
    ..Clinicians can use these nomograms to counsel individual patients and help them make important decisions regarding their disease...
  14. ncbi request reprint Isolated local recurrence is rare after radical prostatectomy in men with Gleason 7 prostate cancer and positive surgical margins: therapeutic implications
    M Han
    Department of Urology, James Buchanan Brady Urological Institute, The Johns Hopkins Medical Institutions, Baltimore, Maryland, USA
    J Urol 165:864-6. 2001
    ..To improve the outcome in cases of Gleason score 7 disease and positive surgical margins a systemic approach to adjuvant therapy is necessary...
  15. ncbi request reprint Substratification of stage T1C prostate cancer based on the probability of biochemical recurrence
    Matthew B Gretzer
    James Buchanan Brady Urological Institute, Johns Hopkins Medical Institutions, Baltimore, Maryland, USA
    Urology 60:1034-9. 2002
    ....
  16. ncbi request reprint Long-term cancer control of radical prostatectomy in men younger than 50 years of age: update 2003
    Masood A Khan
    Department of Urology, James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, Johns Hopkins Hospital, Baltimore, Maryland 21287, USA
    Urology 62:86-91; discussion 91-2. 2003
    ..7% to 4%). Previous studies, mostly carried out before the PSA era, reported conflicting data with respect to cancer control for these younger men treated with RRP...
  17. ncbi request reprint Quantitative alterations in nuclear structure predict prostate carcinoma distant metastasis and death in men with biochemical recurrence after radical prostatectomy
    Masood A Khan
    The James Buchanan Brady Urological Institute, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21287, USA
    Cancer 98:2583-91. 2003
    ....
  18. ncbi request reprint Expectant management of localized prostate cancer
    Masood A Khan
    James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    Urology 62:793-9. 2003
  19. ncbi request reprint Radical prostatectomy for clinical stage T3a disease
    Stephen J Freedland
    Departments of Urology and Oncology, James Buchanan Brady Urological Institute, Johns Hopkins Medicine, Baltimore, Maryland, USA
    Cancer 109:1273-8. 2007
    ..The long-term outcomes among men treated with radical prostatectomy for clinical stage T3a disease were examined...
  20. ncbi request reprint Influence of biopsy perineural invasion on long-term biochemical disease-free survival after radical prostatectomy
    Kiaran J O'Malley
    James Buchanan Brady Urological Institute and Department of Pathology, Johns Hopkins University Medical Institutions, Baltimore, Maryland 21287, USA
    Urology 59:85-90. 2002
    ..However, the histologic identification of PNI on prostate biopsy has been associated with a decreased likelihood of pathologically organ-confined disease...
  21. ncbi request reprint Clinical and pathologic outcome after radical prostatectomy for prostate cancer patients with a preoperative Gleason sum of 8 to 10
    Patrick J Bastian
    James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    Cancer 107:1265-72. 2006
    ....
  22. ncbi request reprint Era specific biochemical recurrence-free survival following radical prostatectomy for clinically localized prostate cancer
    M Han
    Departments of Urology, Oncology Biostatistics and Pathology, James Buchanan Brady Urological Institute, The Johns Hopkins Medical Institutions, Baltimore, Maryland, USA
    J Urol 166:416-9. 2001
    ..When trying to compare the efficacy of different treatment modalities for prostate cancer, the era in which patients underwent therapy is an important factor to be considered...
  23. ncbi request reprint Evaluation of artificial neural networks for the prediction of pathologic stage in prostate carcinoma
    M Han
    James Buchanan Brady Urological Institute, Department of Urology, Johns Hopkins Hospital, Baltimore, Maryland 21287, USA
    Cancer 91:1661-6. 2001
    ..They then compared the results of ANN with the previous nomograms...
  24. ncbi request reprint What does prostate-specific antigen recurrence mean?
    C R Pound
    Department of Urology, The University of Tennessee College of Medicine, 1211 Union Avenue, Suite 340, Memphis, TN 38104, USA
    Curr Urol Rep 1:28-35. 2000
    ..Fortunately, recent developments in determining the significance of a PSA recurrence may help the patient and his physician to make a more informed decision regarding treatment options...
  25. ncbi request reprint Gleason score 7 prostate cancer on needle biopsy: is the prognostic difference in Gleason scores 4 + 3 and 3 + 4 independent of the number of involved cores?
    Danil V Makarov
    Department of Pathology, The James Buchanan Brady Urological Institute, The Johns Hopkins Medical Institutions, Baltimore, Maryland, USA
    J Urol 167:2440-2. 2002
    ..This practice would remove a source of poor interobserver reproducibility when grading prostate cancer on needle biopsy...
  26. ncbi request reprint Death in patients with recurrent prostate cancer after radical prostatectomy: prostate-specific antigen doubling time subgroups and their associated contributions to all-cause mortality
    Stephen J Freedland
    Department of Urology, The James Buchanan Brady Urological Institute, Johns Hopkins Medicine, Baltimore, MD, USA
    J Clin Oncol 25:1765-71. 2007
    ..However, given the small number of patients in the highest risk PSADT subgroup, it is unclear which PSADT subgroups contribute the greatest to prostate cancer-specific death and how this influences all-cause mortality...
  27. ncbi request reprint Preoperative serum DNA GSTP1 CpG island hypermethylation and the risk of early prostate-specific antigen recurrence following radical prostatectomy
    Patrick J Bastian
    The James Buchanan Brady Urological Institute and Department of Urology, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21231 1000, USA
    Clin Cancer Res 11:4037-43. 2005
    ..We evaluated circulating cell-free DNA GSTP1 CpG island hypermethylation as a prognostic biomarker in the serum of men with prostate cancer...
  28. ncbi request reprint Can prostate specific antigen derivatives and pathological parameters predict significant change in expectant management criteria for prostate cancer?
    Masood A Khan
    James Buchanan Brady Urological Institute, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21287, USA
    J Urol 170:2274-8. 2003
    ..Therefore, we determined whether biomarkers could be used to determine those in whom disease is likely to progress and thus those who require definitive therapy...
  29. ncbi request reprint Prediction of pathological stage in patients with clinical stage T1c prostate cancer: the new challenge
    Robert W Veltri
    Brady Urological Institute of The Johns Hopkins Medical Institutions, Baltimore, Maryland 21287 2101, USA
    J Urol 168:100-4. 2002
    ..We developed an algorithm for predicting the likelihood of organ confined disease in patients with clinical stage T1c prostate cancer using biopsy pathology, computer assisted image analysis and serum prostate specific antigen (PSA)...
  30. ncbi request reprint Volume indexes of total, free, and complexed prostate-specific antigen enhance prediction of extraprostatic disease extension in men with nonpalpable prostate cancer
    Yoshio Naya
    Department of Urology, University of Texas M D Anderson Cancer Center, Houston 77030 4095, USA
    Urology 62:1058-62. 2003
    ..To analyze the ability of volume-adjusted total, complexed, and free prostate-specific antigen (PSA) to predict organ-confined cancer at radical prostatectomy in patients with nonpalpable disease...
  31. ncbi request reprint Complexed prostate-specific antigen for the diagnosis of biochemical recurrence after radical prostatectomy
    J Kellogg Parsons
    James Buchanan Brady Urological Institute, The Johns Hopkins Medical Institution, Baltimore, MD, USA
    BJU Int 99:758-61. 2007
    ..To determine the validity of using complexed prostate-specific antigen (cPSA) levels for diagnosing biochemical recurrence after radical prostatectomy (RP)...
  32. ncbi request reprint Prostate cancer in native Japanese and Japanese-American men: effects of dietary differences on prostatic tissue
    Leonard S Marks
    Department of Urology, University of California, Los Angeles, Geffen School of Medicine, Los Angeles, California, USA
    Urology 64:765-71. 2004
    ..To investigate the relationship between diet and prostate cancer (CaP) among native Japanese (NJ) and second-generation or third-generation Japanese-American (J-A) men--focusing on the effects of animal fat and soy on prostatic tissues...
  33. ncbi request reprint Prognostic value of preoperative serum cell-free circulating DNA in men with prostate cancer undergoing radical prostatectomy
    Patrick J Bastian
    The James Buchanan Brady Urological Institute, Department of Urology, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    Clin Cancer Res 13:5361-7. 2007
    ..We evaluated the association of preoperative serum cell-free circulating DNA concentration in men with clinically localized prostate cancer who underwent radical prostatectomy with prostate-specific antigen (PSA) recurrence...
  34. ncbi request reprint Percent free prostate specific antigen in the total prostate specific antigen 2 to 4 ng./ml. range does not substantially increase the number of biopsies needed to detect clinically significant prostate cancer compared to the 4 to 10 ng./ml. range
    Alexander Haese
    James Buchanan Brady Urological Institute, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    J Urol 168:504-8. 2002
    ..Results were compared to those obtained from a reference group of patients (PSA 4 to 10 ng./ml., benign digital rectal examination) from the same prospective referral cohort...
  35. ncbi request reprint Prognostic significance of Gleason score discrepancies between needle biopsy and radical prostatectomy
    Michael Muntener
    Department of Urology, The Johns Hopkins Medical Institutions, Baltimore, MD, USA
    Eur Urol 53:767-75; discussion 775-6. 2008
    ..The objective of this study was to evaluate the prognostic significance of these discrepancies with respect to outcomes following RP...
  36. pmc Phase II, randomized, placebo-controlled trial of neoadjuvant celecoxib in men with clinically localized prostate cancer: evaluation of drug-specific biomarkers
    Emmanuel S Antonarakis
    Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, Baltimore, MD 21231, USA
    J Clin Oncol 27:4986-93. 2009
    ..We conducted a randomized, double-blind trial to examine the effect of celecoxib on drug-specific biomarkers from prostate tissue obtained at prostatectomy...
  37. ncbi request reprint Complexed prostate-specific antigen as a staging tool: results based on a multicenter prospective evaluation of complexed prostate-specific antigen in cancer diagnosis
    Samir S Taneja
    Department of Urology, New York University School of Medicice, NY, USA
    Urology 60:10-7. 2002
    ..Therefore, cPSA could be applied as an accurate predictor of ECE independently or in a nomogram along with other predictive variables...
  38. pmc Prognostic value of Her-2/neu and DNA index for progression, metastasis and prostate cancer-specific death in men with long-term follow-up after radical prostatectomy
    Sumit Isharwal
    The James Buchanan Brady Urological Institute, The Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA
    Int J Cancer 123:2636-43. 2008
    ..Further, Her-2/neu expression and %DNA index may be used with clinicopathologic parameters for prediction of long-term prognosis in PCa...
  39. ncbi request reprint Validation of a biopsy-based pathologic algorithm for predicting lymph node metastases in patients with clinically localized prostate carcinoma
    Alexander Haese
    Department of Urology, James Buchanan Brady Urological Institute, The Johns Hopkins University Medical Institution, Baltimore, Maryland 21287, USA
    Cancer 95:1016-21. 2002
    ..The algorithm was applied to sextant biopsy material and radical retropubic prostatectomy (RRP) stage obtained from a cohort of men who were treated at the authors' institution...
  40. ncbi request reprint Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer
    Misop Han
    James Buchanan Brady Urological Institute, Departments of Urology, Oncology and Pathology, The Johns Hopkins Medical Institutions, Baltimore, Maryland, USA
    J Urol 169:517-23. 2003
    ..We then used those indicators to develop multivariate models for determination of recurrence probability following radical retropubic prostatectomy...
  41. pmc p300 (histone acetyltransferase) biomarker predicts prostate cancer biochemical recurrence and correlates with changes in epithelia nuclear size and shape
    Sumit Isharwal
    James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland 21287, USA
    Prostate 68:1097-104. 2008
    ..Therefore, we evaluated the prognostic value of p300 expression and its correlation with nuclear alterations seen in tumor cells in men with long-term follow-up after radical prostatectomy (RP)...
  42. ncbi request reprint The natural history of metastatic progression in men with PSA-recurrent prostate cancer after radical prostatectomy: 25-year follow-up
    E S Antonarakis
    Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD Brady Urological Institute, Johns Hopkins, Baltimore, MD
    J Clin Oncol 27:5008. 2009
    ..We now report data reflecting up to 25 years of follow-up...
  43. ncbi request reprint The influence of reversible androgen deprivation on serum prostate-specific antigen levels in men with benign prostatic hyperplasia
    J P Weber
    Department of Urology, Johns Hopkins University School of Medicine, Baltimore, Maryland
    J Urol 141:987-92. 1989
    ..Furthermore, although testosterone determines prostatic size and amount of prostatic epithelium, it may not totally control prostate-specific antigen production...
  44. ncbi request reprint Contemporary identification of patients at high risk of early prostate cancer recurrence after radical retropubic prostatectomy
    W W Roberts
    James Buchanan Brady Urological Institute, Johns Hopkins Medical Institutions, Baltimore, Maryland, USA
    Urology 57:1033-7. 2001
    ..CONCLUSIONS: We have developed a multivariate Cox proportional hazards model that successfully stratifies patients on the basis of their risk of early prostate cancer recurrence...
  45. ncbi request reprint Early prostate cancer antigen expression in predicting presence of prostate cancer in men with histologically negative biopsies
    D E Hansel
    Department of Pathology, The Johns Hopkins University, Baltimore, Maryland 21231, USA
    J Urol 177:1736-40. 2007
    ....
  46. ncbi request reprint Safety and efficacy of exisulind for treatment of recurrent prostate cancer after radical prostatectomy
    E T Goluboff
    Department of Urology, Columbia University, Columbia-Presbyterian Medical Center, Allen Pavilion, 5141 Broadway, New York, NY 10034, USA
    J Urol 166:882-6. 2001
    ..Exisulind was well tolerated in this patient population. Our results support further study of Exisulind in the treatment of patients with prostate cancer...
  47. ncbi request reprint Age, prostate-specific antigen, and digital rectal examination as determinants of the probability of having prostate cancer
    S R Potter
    James Buchanan Brady Urological Institute, Johns Hopkins Hospital, Baltimore, Maryland 21287-2101, USA
    Urology 57:1100-4. 2001
    ..These data may aid physicians and patients in decision-making...
  48. ncbi request reprint Alterations in nuclear structure and expression of proPSA predict differences between native Japanese and Japanese-American prostate cancer
    Robert W Veltri
    Department of Urology, Johns Hopkins Medical Institutions, Baltimore, Maryland, USA
    Urology 68:898-904. 2006
    ..To differentiate the benign and/or malignant epithelial cells in prostate cancer (PCa) glands of native Japanese (NJ) and Japanese-American (JA) men using biomarkers...
  49. pmc Analysis of a serum test for prostate cancer that detects a second epitope of EPCA-2
    Eddy S Leman
    The Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland 21287, USA
    Prostate 69:1188-94. 2009
    ..19. The goals of this study are to characterize the sensitivity and specificity of the EPCA-2.19 assay, in a non-screening population, and to demonstrate that such test based has similar characteristics as the initial assay produced...
  50. doi request reprint External validation of University of California, San Francisco, Cancer of the Prostate Risk Assessment score
    Kevin H Zhao
    Department of Urology, James Buchanan Brady Urological Institute, Johns Hopkins Medical Institutions, Baltimore, Maryland 21287, USA
    Urology 72:396-400. 2008
    ..This study provides external validation and a modified version of the model using a large cohort of men treated with radical prostatectomy at a high-volume, tertiary referral center...
  51. pmc Endoglin (CD105) as a urinary and serum marker of prostate cancer
    Kazutoshi Fujita
    Brady Urological Institute, Johns Hopkins Medical Institutions, Baltimore, MD 21224, USA
    Int J Cancer 124:664-9. 2009
    ..Endoglin levels in both urine and serum may aid in prostate cancer detection and prognostication...
  52. pmc Does laterality of positive needle biopsy in clinical T2a patients with prostate cancer affect biochemical recurrence-free survival?
    Ina Wu
    James Buchanan Brady Urological Institute, Department of Urology, Johns Hopkins Hospital, Baltimore, Maryland, USA
    Urology 72:1219-23. 2008
    ..To test whether patients with clinical Stage T2a prostate cancer with biopsy-proven disease only contralateral to the palpable abnormality experience outcomes similar to those of patients with clinical Stage T1c...
  53. ncbi request reprint Nomograms for clinically localized prostate cancer. Part I: radical prostatectomy
    Misop Han
    James Buchanan Brady Urological Institute, The Department of Urology, The Johns Hopkins Medical Institutions, Baltimore, MD, USA
    Semin Urol Oncol 20:123-30. 2002
    ..These nomograms can help patients understand the long-term cancer cure rates after radical prostatectomy...
  54. ncbi request reprint Saw palmetto alters nuclear measurements reflecting DNA content in men with symptomatic BPH: evidence for a possible molecular mechanism
    Robert W Veltri
    Department of Urology, Johns Hopkins Medical Institutions, Baltimore, Maryland, USA
    Urology 60:617-22. 2002
    ..Saw palmetto herbal blend (SPHB) causes contraction of prostate epithelial cells and suppression of tissue dihydrotestosterone levels in men with symptomatic benign prostatic hyperplasia, but a fundamental mechanism remains unknown...
  55. ncbi request reprint Promoter hypermethylation as an independent prognostic factor for relapse in patients with prostate cancer following radical prostatectomy
    Eli Rosenbaum
    Department of Otolaryngology Head and Neck Surgery, Head and Neck Cancer Research Division, John Hopkins School of Medicine, Baltimore, MD 21205 2196, USA
    Clin Cancer Res 11:8321-5. 2005
    ..To analyze the prognostic significance of six epigenetic biomarkers (APC, Cyclin D2, GSTP1, TIG1, Rassf1A, and RARbeta2 promoter hypermethylation) in a homogeneous group of prostate cancer patients, following radical prostatectomy alone...
  56. ncbi request reprint Biopsy indication--a predictor of pathologic stage among men with preoperative serum PSA levels of 4.0 ng/mL or less and T1c disease
    Stephen J Freedland
    James Buchanan Brady Urological Institute, Department of Urology, Johns Hopkins School of Medicine, Baltimore, Maryland 21287 2101, USA
    Urology 63:887-91. 2004
    ..It is not uncommon for men to undergo radical prostatectomy (RP) with a prostate-specific antigen (PSA) level of 4 ng/mL or less and T1c disease...
  57. ncbi request reprint Survival following early hormone therapy for men with rapid PSA doubling time within 2 years following radical prostatectomy
    B Trock
    Johns Hopkins School of Medicine, Baltimore, MD
    J Clin Oncol 27:5065. 2009
    ..We examined the impact of salvage hormonal therapy on overall survival (OS) in a cohort with long-term follow-up, and attempted to identify the subgroup most likely to benefit...
  58. ncbi request reprint Indicators of pathologic stage of prostate cancer and their use in clinical practice
    M R Feneley
    Department of Urology, James Buchanan Brady Urological Institute, Johns Hopkins Medical Institutions, Baltimore, Maryland, USA
    Urol Clin North Am 28:443-58. 2001
    ..For patients undergoing radical prostatectomy, definitive pathologic stage certainly will remain an important prognostic factor; therefore, clinical practice will continue to be determined by its accurate prediction...
  59. pmc CpG island hypermethylation profile in the serum of men with clinically localized and hormone refractory metastatic prostate cancer
    Patrick J Bastian
    James Buchanan Brady Urological Institute, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    J Urol 179:529-34; discussion 534-5. 2008
    ..In this study we investigated the hypermethylation profile of several genes in the serum of men with localized and hormone refractory prostate cancer...
  60. ncbi request reprint Contemporary evaluation of the D'amico risk classification of prostate cancer
    David J Hernandez
    Department of Urology, James Buchanan Brady Urological Institute, Johns Hopkins Medical Institutions, Baltimore, Maryland 21287, USA
    Urology 70:931-5. 2007
    ..We studied the performance and clinical relevance of this classification system over time, in the context of the stage migration seen in the contemporary era, using data from a high-volume, tertiary referral center...
  61. ncbi request reprint Complexed prostate-specific antigen as a staging tool for prostate cancer: a prospective study in 420 men
    Lori J Sokoll
    Department of Pathology, The Johns Hopkins Medical Institutions, Baltimore, Maryland 21287, USA
    Urology 60:18-23. 2002
    ..985). In summary, cPSA was equivalent to total PSA in predicting organ-confined disease. Present and future models and nomograms using PSA as an indicator of pathological stage could consider use of cPSA...
  62. doi request reprint Is it possible to compare PSA recurrence-free survival after surgery and radiotherapy using revised ASTRO criterion--"nadir + 2"?
    Matthew E Nielsen
    James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland 21287 2101, USA
    Urology 72:389-93; discussion 394-5. 2008
    ..Because this definition inevitably will be used to compare cancer control rates after radiotherapy to those after surgery, this study examined the effect of this comparison...
  63. pmc Using nuclear morphometry to predict the need for treatment among men with low grade, low stage prostate cancer enrolled in a program of expectant management with curative intent
    Danil V Makarov
    Department of Urology, The James Buchanan Brady Urological Institute, The Johns Hopkins Medical Institutions, Baltimore, Maryland 21287, USA
    Prostate 68:183-9. 2008
    ..We assessed the use of quantitative clinical and pathologic information to predict which patients would eventually require treatment for prostate cancer (CaP) in an expectant management (EM) cohort...
  64. pmc Prostate specific antigen versus prostate specific antigen density as a prognosticator of pathological characteristics and biochemical recurrence following radical prostatectomy
    Ahmed Magheli
    Department of Urology, The James Buchanan Brady Urological Institute, The Johns Hopkins Medical Institutions, Baltimore, Maryland, USA
    J Urol 179:1780-4; discussion 1784. 2008
    ..We investigated whether prostate specific antigen density yielded an advantage over total prostate specific antigen for predicting adverse pathological characteristics and disease recurrence following radical prostatectomy...
  65. pmc Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy
    Bruce J Trock
    Brady Urological Institute, Johns Hopkins School of Medicine, 600 N Wolfe St, 546 Phipps Bldg, Baltimore, MD 21287, USA
    JAMA 299:2760-9. 2008
    ....
  66. pmc Long-term assessment of prostate cancer progression free survival: evaluation of pathological parameters, nuclear shape and molecular biomarkers of pathogenesis
    Robert W Veltri
    James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland 21287, USA
    Prostate 68:1806-15. 2008
    ..Therefore, we evaluated the prognostic value of these parameters in 105 clinically localized PCa tumors with long-term follow-up after radical prostatectomy for progression-free survival (PFS)...
  67. pmc Predicting the outcome of prostate biopsy: comparison of a novel logistic regression-based model, the prostate cancer risk calculator, and prostate-specific antigen level alone
    David J Hernandez
    Johns Hopkins Medical Institutions, Baltimore, MD 21287, USA
    BJU Int 103:609-14. 2009
    ....
  68. pmc Small integrin-binding proteins as serum markers for prostate cancer detection
    Alka Jain
    Division of Geriatric Medicine and Gerontology, Department of Medicine, Johns Hopkins University, Baltimore, Maryland, USA
    Clin Cancer Res 15:5199-207. 2009
    ..Previous studies have separately reported elevated expression of BSP, OPN, or DSPP in prostate tumor paraffin sections. We hypothesized that SIBLINGs may be informative serum markers for subjects with prostate cancer...
  69. pmc The impact of preoperative erectile dysfunction on survival after radical prostatectomy
    Misop Han
    James Buchanan Brady Urological Institute, Johns Hopkins Medical Institutions, Baltimore, MD, USA
    BJU Int 106:1612-7. 2010
    ..The underlying pathology for preoperative ED may adversely affect survival following radical prostatectomy (RP). We examined the association between preoperative ED and survival following RP...
  70. doi request reprint Nuclear roundness variance predicts prostate cancer progression, metastasis, and death: A prospective evaluation with up to 25 years of follow-up after radical prostatectomy
    Robert W Veltri
    James Buchanan Brady Urological Institute, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21287, USA
    Prostate 70:1333-9. 2010
    ..Therefore, we evaluated the prognostic value of nuclear roundness variance (NRV) for prostate cancer (PCa) progression, metastasis and PCa-specific death free survivals in a cohort of 116 men after radical prostatectomy (RP)...
  71. ncbi request reprint Prostate-specific antigen as a marker of disease activity in prostate cancer
    Alan W Partin
    Johns Hopkins University, School of Medicine, Baltimore, Maryland 21287, USA
    Oncology (Williston Park) 16:1024-38, 1042; discussion 1042, 1047-8, 1051. 2002
    ..Part 1 of this two-part article, which concludes in the September issue, focuses on the physiology of PSA, its measurement and use in clinical practice, and its predictive value following radical prostatectomy and radiation therapy...
  72. ncbi request reprint Immunohistochemical staining of prostate cancer with monoclonal antibodies to the precursor of prostate-specific antigen
    Theresa Y Chan
    Department of Pathology, Johns Hopkins Hospital, Baltimore, Maryland 21231, USA
    Urology 62:177-81. 2003
    ..Pro-PSA have previously been shown to be more concentrated in prostate cancer tissue extracts than in benign tissue...
  73. ncbi request reprint Natural history of disease progression in patients who fail to achieve an undetectable prostate-specific antigen level after undergoing radical prostatectomy
    Craig G Rogers
    The James Buchanan Brady Urological Institute, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    Cancer 101:2549-56. 2004
    ..The authors assessed the clinical outcome of men with a persistently detectable PSA level after RRP for clinically localized prostate carcinoma...
  74. ncbi request reprint Complexed prostate specific antigen (PSA) reduces unnecessary prostate biopsies in the 2.6-4.0 ng/mL range of total PSA
    J Kellogg Parsons
    The James Buchanan Brady Urological Institute, The Johns Hopkins Medical Institutions Baltimore, MD 21287, USA
    BJU Int 94:47-50. 2004
    ..To compare the performance of complexed prostate-specific antigen (cPSA) to total PSA (tPSA) and percentage free PSA (f/tPSA) in the diagnosis of prostate cancer for the tPSA range 2.6-4.0 ng/mL...
  75. ncbi request reprint Serum leptin and pathological findings at the time of radical prostatectomy
    Stephen J Freedland
    James Buchanan Brady Urological Institute and the Department of Urology, The Johns Hopkins Medical Institutions, Baltimore, Maryland, USA
    J Urol 173:773-6. 2005
    ..Obese men have higher serum leptin, a hormone produced by adipocytes, which has also been shown to be an in vitro prostate cancer growth factor. We examined whether serum leptin correlates with advanced pathological findings at RP...
  76. doi request reprint The significance of a positive bladder neck margin after radical prostatectomy: the American Joint Committee on Cancer Pathological Stage T4 designation is not warranted
    Phillip M Pierorazio
    James Buchanan Brady Urological Institute, Johns Hopkins Medical Institutions, Baltimore, Maryland 21287, USA
    J Urol 183:151-7. 2010
    ..We examined biochemical recurrence-free survival and cancer specific survival in men with a positive bladder neck margin...
  77. ncbi request reprint Ability to predict metastasis based on pathology findings and alterations in nuclear structure of normal-appearing and cancer peripheral zone epithelium in the prostate
    Robert W Veltri
    The James Buchanan Brady Urological Institute, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21287, USA
    Clin Cancer Res 10:3465-73. 2004
    ..The nuclear structure information was combined with routine pathological findings to predict metastatic PCa progression and/or death...
  78. ncbi request reprint Efficacy of continuous local anesthetic infusion for postoperative pain after radical retropubic prostatectomy
    Christopher L Wu
    Department of Anesthesiology and Critical Care Medicine, Johns Hopkins University, Baltimore, Maryland 21287, USA
    Urology 66:366-70. 2005
    ..To determine whether a subfascial continuous infusion of local anesthetic in patients undergoing radical retropubic prostatectomy would result in a reduction in postoperative opioid requirements and an improvement in pain scores...
  79. ncbi request reprint Obesity and risk of biochemical progression following radical prostatectomy at a tertiary care referral center
    Stephen J Freedland
    Department of Urology, The Johns Hopkins School of Medicine, Baltimore, Maryland 21287 2101, USA
    J Urol 174:919-22. 2005
    ..We sought to validate or refute these findings using data on men treated by multiple other surgeons at our institution...
  80. ncbi request reprint Relationship between primary Gleason pattern on needle biopsy and clinicopathologic outcomes among men with Gleason score 7 adenocarcinoma of the prostate
    Mark L Gonzalgo
    Department of Urology, James Buchanan Brady Urological Institute, Johns Hopkins Medical Institutions, Baltimore, Maryland, USA
    Urology 67:115-9. 2006
    ..To examine the relationship among needle biopsy primary grade, prostatectomy grade, and postprostatectomy biochemical recurrence among men with Gleason score 7 disease...
  81. ncbi request reprint The design of a randomized, placebo-controlled trial of celecoxib in preprostatectomy men with clinically localized adenocarcinoma of the prostate
    Elisabeth I Heath
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231, USA
    Clin Prostate Cancer 1:182-7. 2002
  82. ncbi request reprint Biochemical failure after radical prostatectomy in men with pathologic organ-confined disease: pT2a versus pT2b
    Stephen J Freedland
    Department of Urology, The Johns Hopkins Medical Institutions, Baltimore, Maryland 21287, USA
    Cancer 100:1646-9. 2004
    ..Whether this distinction provides prognostic significance is unclear. The authors evaluated biochemical outcomes between men with pT2aN0 and pT2bN0 disease...
  83. ncbi request reprint Proteomic analysis of dunning prostate cancer cell lines with variable metastatic potential using SELDI-TOF
    M B Gretzer
    The Brady Urological Institute, Johns Hopkins Medical Institutions, Baltimore, Maryland, USA
    Prostate 60:325-31. 2004
    ....
  84. ncbi request reprint Stromal-epithelial measurements of prostate cancer in native Japanese and Japanese-American men
    R W Veltri
    James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA
    Prostate Cancer Prostatic Dis 7:232-7. 2004
    ....
  85. ncbi request reprint Executive Summary of the National Cancer Institute Workshop: Highlights and recommendations
    R Lieberman
    National Cancer Institute, Rockville, Maryland, USA
    Urology 57:4-27. 2001
    ..Finally, each expert panel generated recommendations for areas of future research emphasizing opportunities and infrastructure needs...
  86. ncbi request reprint Expectant management: an option for localized prostate cancer
    M A Khan
    James Buchanan Brady Urological Institute, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21287, USA
    Prostate Cancer Prostatic Dis 8:311-5. 2005
    ..In this brief review, we discuss the evolution of expectant management for men with localized prostate cancer...
  87. ncbi request reprint Bioimpedance: novel use of a minimally invasive technique for cancer localization in the intact prostate
    B R Lee
    James Buchanan Brady Urological Institute, Johns Hopkins Hospital, Baltimore, Maryland 21287, USA
    Prostate 39:213-8. 1999
    ..Our goal was to assess the utility of bioimpedance measurements in differentiating tumor from normal prostatic tissue in an ex vivo model...
  88. ncbi request reprint Expression of metallothionein in seminal vesicles--an immunohistochemical study
    J Pannek
    Department of Urology, Marienhospital Herne, Germany
    Scand J Urol Nephrol 35:11-4. 2001
    ..Metallothionein plays a significant role in the detoxification of heavy metals. Thus, this study investigated the expression of metallothionein in seminal vesicle tissue...
  89. ncbi request reprint Induction of immunity to prostate cancer antigens: results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer
    J W Simons
    Johns Hopkins Oncology Center, Brady Urological Institute, and Johns Hopkins University School of Medicine, Baltimore, Maryland 21287, USA
    Cancer Res 59:5160-8. 1999
    ..No antibodies against prostate-specific antigen were detected. These data suggest that both T-cell and B-cell immune responses to human PCA can be generated by treatment with irradiated, GM-CSF gene-transduced PCA vaccines...
  90. ncbi request reprint The effect of hospital volume on cancer control after radical prostatectomy
    L M Ellison
    Brady Urological Institute, Johns Hopkins Hospital, Baltimore, Maryland, USA
    J Urol 173:2094-8. 2005
    ..For complex oncological procedures, hospital volume affects short and long-term patient outcome. We examined the association of hospital volume and long-term cancer control after radical prostatectomy...
  91. pmc Very-high-risk localized prostate cancer: definition and outcomes
    D Sundi
    Brady Institute of Urology, Johns Hopkins Medical Institutions, Baltimore, MD, USA
    Prostate Cancer Prostatic Dis 17:57-63. 2014
    ..Here, we derive a binary definition of very-high-risk (VHR) localized PCa to aid in risk stratification at diagnosis and selection of therapy...
  92. ncbi request reprint Partin tables: past and present
    M A Khan
    James Buchanan Brady Urological Institute, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21287, USA
    BJU Int 92:7-11. 2003
  93. ncbi request reprint Positive proximal (bladder neck) margin at radical prostatectomy confers greater risk of biochemical progression
    Hakan Aydin
    Department of Pathology, Baskent University Hospital, Ankara, Turkey
    Urology 64:551-5. 2004
    ..To identify the prognostic significance of positive bladder neck margin as the sole positive margin after radical retropubic prostatectomy for treatment of prostate cancer...
  94. ncbi request reprint SELDI protein profiling of dunning R-3327 derived cell lines: identification of molecular markers of prostate cancer progression
    Gunjan Malik
    Center for Biomedical Proteomics, Virginia Prostate Center, Eastern Virginia Medical School, Norfolk, Virginia, USA
    Prostate 67:1565-75. 2007
    ..As a parallel effort, we have been pursuing the identification of the protein(s) comprising the individual discriminatory "peaks" and evaluating their utility as potential biomarkers for prostate cancer progression...
  95. ncbi request reprint Proenzyme psa for the early detection of prostate cancer in the 2.5-4.0 ng/ml total psa range: preliminary analysis
    Lori J Sokoll
    Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD 21287, USA
    Urology 61:274-6. 2003
    ..5 to 4.0 ng/mL total PSA range. pPSA, the precursor form of PSA that contains a 7 amino acid leader peptide, and truncated forms such as [-2]pPSA and [-4]pPSA can be measured in serum by research immunoassay...
  96. doi request reprint PCA3: a molecular urine assay for predicting prostate biopsy outcome
    Ina L Deras
    Gen Probe, Inc, San Diego, California 92121, USA
    J Urol 179:1587-92. 2008
    ..We further characterized PCA3 performance in different groups of men and determined whether the PCA3 score could synergize with other clinical information to predict biopsy outcome...
  97. ncbi request reprint Clinical utility of indium 111-capromab pendetide immunoscintigraphy in the detection of early, recurrent prostate carcinoma after radical prostatectomy
    Ganesh V Raj
    Division of Urology, Duke University Medical Center, Durham, North Carolina 27704, USA
    Cancer 94:987-96. 2002
    ..0 ng/mL) and assessed the minimum serum PSA level necessary for imaging recurrent disease...
  98. ncbi request reprint Effect of testosterone replacement therapy on prostate tissue in men with late-onset hypogonadism: a randomized controlled trial
    Leonard S Marks
    Department of Urology, Geffen School of Medicine, University of California, Los Angeles, USA
    JAMA 296:2351-61. 2006
    ..Prostate safety is a primary concern when aging men receive testosterone replacement therapy (TRT), but little information is available regarding the effects of TRT on prostate tissue in men...
  99. ncbi request reprint Management of patients with an increasing prostate-specific antigen after radical prostatectomy
    Masood A Khan
    James Buchanan Brady Urological Institute, Johns Hopkins Hospital, Jefferson Building, Room 157, 600 North Wolfe Street, Baltimore, MD 21287 2101, USA
    Curr Urol Rep 5:179-87. 2004
    ..Factors indicating whether the increasing serum PSA is caused by local recurrence or metastatic disease and the management options available to address serum PSA recurrence also are discussed...
  100. pmc [-2]proenzyme prostate specific antigen for prostate cancer detection: a national cancer institute early detection research network validation study
    Lori J Sokoll
    Departments of Pathology and Urology, Johns Hopkins Medical Institutions, Baltimore, Maryland, USA
    J Urol 180:539-43; discussion 543. 2008
    ..This study evaluated the [-2]proenzyme prostate specific antigen serum marker using a blinded reference specimen set from 3 National Cancer Institute Early Detection Research Network centers from men with an indication for prostate biopsy...
  101. ncbi request reprint Comparative analysis of complexed prostate specific antigen, free prostate specific antigen and their ratio in detecting prostate cancer
    Koji Okihara
    University of Texas M D Anderson Cancer Center, Houston, Texas 77030 4009, USA
    J Urol 167:2017-23; discussion 2023-4. 2002
    ..We evaluate the diagnostic use of total, free and complexed serum prostate specific antigen (PSA), and their ratios for enhancing the specificity in detecting prostate cancer...